ECE2018 Poster Presentations: Diabetes, Obesity and Metabolism Diabetes therapy (43 abstracts)
Hospital Universitario Reina Sofía, Córdoba, Spain.
Objective: To evaluate the efficacy of canagliflozin 100 mg for glycemic control and progression of weight loss after stabilization with liraglutide 1.8 mg.
Patients and methods: Descriptive study: patients with type 2 diabetes (DM-2) in treatment with metformin and liraglutide 1.8 mg, optimal metabolic control, which after stabilization in weight loss, liraglutide is suspended and canagliflozin 100 mg is added. Variables analyzed baseline and at 6 months after treatment change: age, sex, time of diabetes evolution, Body mass index (BMI), abdominal perimeter (BP), systolic blood pressure (SBP), diastolic blood pressure (DBP), LDL, HDL, triglycerides (TG), uric acid (UA). Statistical analysis: comparing means with Students test.
Results: Eighteen patients. 50% women Age: 55.61±7.1 years. Time of diabetes evolution: 7.7±5 years. Weight loss achieved 6 months after the change of treatment was 6±2.5 Kg. No side effects were recorded. The treatment change was satisfactory for all patients.
Basal (mean ± SD) | 6 months (mean ± SD) | P | |
Weight (Kg) | 97.5±10.8 | 91±10.9 | 0.1 |
BMI (kg/m2) | 35.2±2.3 | 33.1±2.2 | 0.01 |
BP (cm) | 110.3±9.4 | 105.7±8.6 | 0.1 |
SBP (mmHg) | 137.5±8.5 | 128.9±7.1 | 0.002 |
DBP (mmHg) | 84.6±14.4 | 75.5±7.1 | 0.02 |
HbA1c (%) | 7±0.2 | 6.5±0.3 | 0.000 |
LDL (mg/dl) | 104.5±32.1 | 89.3±22 | 0.11 |
HDL (mg/dl) | 46.8±8 | 49.5±6.7 | 0.3 |
TG (mg/dl) | 164.5±74.2 | 125.8±44.4 | 0.06 |
UA (mg/dl) | 7.2±0.9 | 6.5±1.2 | 0.05 |
Conclusions: The change of treatment of liraglutide 1.8 mg to canagliflozin 100 mg in patients with optimal glycemic control and stabilization weight loss, achieves a progression in weight loss and improves the metabolic control of the patient with DM-2. The change of treatment was satisfactory for all patients. No side effects were recorded.